MX2020004837A - Inhibidores de la vía de adenosina para el tratamiento del cáncer. - Google Patents

Inhibidores de la vía de adenosina para el tratamiento del cáncer.

Info

Publication number
MX2020004837A
MX2020004837A MX2020004837A MX2020004837A MX2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A
Authority
MX
Mexico
Prior art keywords
inhibitors
cancer
treatment
adenosine pathway
adenosine
Prior art date
Application number
MX2020004837A
Other languages
English (en)
Inventor
Richard A Miller
Andrew Hotson
Ian Mccaffery
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2020004837A publication Critical patent/MX2020004837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ecology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan en la presente, entre otros, los métodos para tratar el cáncer en sujetos que expresan niveles elevados de receptores A2A de adenosina, y opcionalmente que expresan niveles elevados de CD73 y/o PD-L1, mediante la administración de inhibidores de la vía de adenosina.
MX2020004837A 2017-11-06 2018-11-06 Inhibidores de la vía de adenosina para el tratamiento del cáncer. MX2020004837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582246P 2017-11-06 2017-11-06
PCT/US2018/059480 WO2019090347A1 (en) 2017-11-06 2018-11-06 Adenosine pathway inhibitors for cancer treatment

Publications (1)

Publication Number Publication Date
MX2020004837A true MX2020004837A (es) 2020-08-13

Family

ID=66332406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004837A MX2020004837A (es) 2017-11-06 2018-11-06 Inhibidores de la vía de adenosina para el tratamiento del cáncer.

Country Status (10)

Country Link
US (1) US20210008206A1 (es)
EP (1) EP3706753A4 (es)
JP (1) JP2021502342A (es)
KR (1) KR20200096921A (es)
CN (1) CN111565722A (es)
AU (1) AU2018359894A1 (es)
CA (1) CA3080976A1 (es)
IL (1) IL274445A (es)
MX (1) MX2020004837A (es)
WO (1) WO2019090347A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391382B (es) * 2015-12-24 2025-03-21 Corvus Pharmaceuticals Inc Métodos de tratamiento de cáncer
KR20200040764A (ko) 2017-07-18 2020-04-20 누베이션 바이오 인크. 1,8-나프티리디논 화합물 및 그의 용도
CA3070273A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
EP3820522A4 (en) 2018-07-12 2022-05-18 Corvus Pharmaceuticals, Inc. METHODS OF DETECTION AND THERAPY OF CANCER WITH ACTIVATION OF THE ADENOSIN SIGNALING PATHWAY
KR102767594B1 (ko) 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
CA3126931A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CA3126702A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
EP3937964B1 (en) 2019-03-12 2026-03-11 Arcus Biosciences, Inc. Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US12570750B2 (en) 2019-12-09 2026-03-10 Twist Bioscience Corporation Antibodies that bind adenosine A2A receptors and methods of use thereof to treat cancer and neurological diseases
BR112022021426A2 (pt) * 2020-04-22 2022-12-13 Akeso Biopharma Inc Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73
US12202905B2 (en) * 2021-01-21 2025-01-21 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
TW202245774A (zh) * 2021-02-05 2022-12-01 大陸商上海齊魯製藥研究中心有限公司 嘧啶或吡啶並雜環類腺苷受體抑制劑及其製備方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
US20170242016A1 (en) * 2014-10-15 2017-08-24 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1
MX391382B (es) * 2015-12-24 2025-03-21 Corvus Pharmaceuticals Inc Métodos de tratamiento de cáncer
US20190284293A1 (en) * 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies

Also Published As

Publication number Publication date
EP3706753A1 (en) 2020-09-16
JP2021502342A (ja) 2021-01-28
US20210008206A1 (en) 2021-01-14
IL274445A (en) 2020-06-30
CN111565722A (zh) 2020-08-21
WO2019090347A1 (en) 2019-05-09
WO2019090347A8 (en) 2019-06-13
EP3706753A4 (en) 2021-12-22
AU2018359894A1 (en) 2020-05-21
CA3080976A1 (en) 2019-05-09
KR20200096921A (ko) 2020-08-14

Similar Documents

Publication Publication Date Title
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX2025002382A (es) Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
MX2017014375A (es) Moduladores del ccr2.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2017005553A (es) Terapia de combinacion para cancer.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
MX2017013178A (es) Terapia de combinacion para cancer.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
MX391720B (es) Terapia combinada para tratar cáncer.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.